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Background: Genetic, epidemiologic, and clinical evidence suggests that, in horses, there are
manifestations of hypersensitivity that can occur together.
Objectives: To investigate whether concurrent insect bite hypersensitivity (IBH) and severe
equine asthma (EA) is associated with higher allergen-specific and total serum immunoglobulin E
(IgE) concentrations than only EA or IBH.
Animals: Healthy control horses (C, n = 40), horses with IBH (IBH, n = 24), severe EA (EA,
n = 18), and both conditions (IBH/EA, n = 23) were included.
Methods: In our retrospective comparative study, sera from horses with signs of severe EA,
IBH, and control animals were used. IgE specific for 15 recombinant (r) allergens as well as total
serum IgE concentrations were measured by enzyme-linked immunosorbent assay.
Results: Group IBH (median sum r-Culicoides IgE: optical density at 405 nm [OD405] = 3.54
[0.48-15.07]) and group IBH/EA (OD405 = 4.55 [0.46-17.15]) had significantly (P < .001) higher
IgE against Culicoides r-allergens than groups C (OD405 = 0.44 [0.21-2.05]) and EA (OD405 = 0.6
[0.2-2.9]). There were no significant (P > .05) differences between group IBH and group
IBH/EA. No significant differences among the groups were found for the other r-allergens or
total serum IgE concentration. Compared to controls, horses with severe IBH had significantly
increased IgE concentration to 5 Culicoides r-allergens (P < .05), whereas horses with moderate
IBH had significantly increased IgE concentration to only 3 Culicoides r-allergens (P < .05).
Conclusions and Clinical Importance: Susceptibility of IBH-affected horses to develop EA is likely
not associated with IgE-mediated immune reactions but with other immunopathological
mechanisms.
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1 | INTRODUCTION
Genetic, epidemiologic, and clinical evidence suggests that, in horses,
as in other species, different manifestations of hypersensitivity occur
concurrently.1,2 In humans, the “atopic march” manifests as a temporal
sequence of hypersensitivities, with atopic dermatitis in the neonate
preceding the development of allergic rhinitis and asthma.3 The atopic
march and multiple allergies in humans can be associated with
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increased total serum immunoglobulin E (IgE), IgE cross-reactivity
between different allergens, or both.3,4
In horses, multiple hypersensitivities can manifest as the com-
bined occurrence of equine asthma (EA), insect bite hypersensitivity
(IBH), and chronic recurrent urticaria. Particularly, the prevalence of
IBH is increased in recurrent airway obstruction (RAO)–affected
horses and vice-versa.1 Although longitudinal studies in affected
horses are lacking, the typical earlier onset of IBH compared to RAO5
suggests that as in humans with multiple hypersensitivity disorder, a
dysfunctional skin barrier serves as the site of allergen sensitization,
resulting in a systemic T-helper-2 immunity which is a predisposing
factor for the development of respiratory allergies.6
IBH is an allergic dermatitis provoked by Culicoides midge bites.5
Affected horses have intense pruritus, which results in typical skin
lesions localized mainly along the dorsal midline and the base of the tail
and the mane.5 The involvement of IgE-mediated reactions in the path-
ogenesis of this disease has been clearly established.5 The specific Culi-
coides allergens causing IBH have been identified at the molecular level
and produced as pure recombinant (r) allergens.5,7,8 The use of these r-
allergens compared to crude Culicoides nubeculosus whole-body extract
improves the sensitivity and specificity of serologic IgE tests for IBH.9
EA encompasses inflammatory airway disease (the mild to moder-
ate form of EA) and RAO, also known as heaves, the severe form.10
Dyspnea, coughing, and loss of performance are the most commonly
observed clinical signs, caused mainly by the bronchoconstriction and
the compromised gas exchange.11 The exact immunopathogenesis of
severe EA remains unclear,12 and the involvement of IgE-mediated
reactions is still controversial, but a part of horses with severe EA
have increased IgE concentrations against r Asp f allergens.13–15 Even
less is known about the pathogenesis and potential involvement of
IgE in the milder forms of EA.10
Based on these findings, the aim of our study was to investigate
allergen-specific IgE concentrations in the sera of healthy control
(C) horses as well as horses with IBH, EA, and both conditions, using a
panel of r-allergens including r Asp f and r-Culicoides allergens. A 2nd
aim was to investigate whether allergic horses had increased serum IgE
concentrations specific for r-allergens not previously tested in the horse
(r-Cladosporium herbarum [r Cla h] 8, r-Glycophagus domesticus [r Gly d]
2, and r-Dermatophagoides pteronyssinus [r Der p] 23). Thus, a panel of
different allergen classes that included midge, mold, and mite r-allergens
was used to test the hypothesis that horses with both conditions, spe-
cifically IBH and EA, have more diverse and augmented reactions across
the allergen classes compared to healthy horses and compared to
horses with IBH or EA alone.
2 | MATERIALS AND METHODS
2.1 | Study design
The serum used in our study was drawn from horses that were
included in 3 previously published studies (Supporting Information
Table S1).2,16,17 The studies were approved by the Animal Experimental
Committees of the Cantons of Berne, Freiburg, Solothurn, and Geneva,
Switzerland (BE10/13; 58/10; 118/16). Four groups were defined using
questionnaire-based and clinical information: healthy controls (group C),
IBH-affected horses (group IBH), severe EA-affected horses (group EA),
and horses with both IBH and EA (group IBH/EA).
Samples from 69 horses included in Lanz et al (2017)2 formed
group IBH (n = 24), group IBH/EA (n = 23), and 22 samples of group
C. Because no horses affected with severe EA only were included in
our study2 and increased concentrations of IgE specific for mold aller-
gens had previously been described in horses with severe EA, samples
from horses with severe EA and matched controls were drawn from
2 previous studies16,17 to form group EA (n = 18) and to complement
group C with 18 controls. Samples were selected based on availability
and on the Horse Owner Assessed Respiratory Signs Index (HOARSI).
2.2 | Serum samples, horse population structures,
and group definitions
Blood was collected from the jugular vein using Serum Clot
Activator-containing vacutainers (Vacuette; GreinerBioOne, St. Gallen,
Switzerland). The blood was centrifuged for 10 minutes at 2000g, and
serum was separated and stored at −80C until used.
For every horse, IBH severity and lung health status were
determined using standardized questionnaires. All horses were with-
drawn from medication for at least 2 weeks before clinical examina-
tion and blood sampling. Some of the horses with asthma had been
treated with corticosteroids, bronchodilators, or both. Preventive
measures such as blankets and repellents were used in some of the
IBH-affected horses to decrease exposure to insects.
The standardized IBH score, based on the most severe clinical signs
the horse had experienced (Supporting Information Table S1), was per-
formed as described.2 Briefly, cutaneous lesions observed on the mane,
tail, head, and ventral midline were classified according to 5 severity
grades ranging from 0 (no signs of IBH) to 5 (bleeding from self-inflicted
abrasions). Horses were classified as IBH-positive, if the IBH score was
>0 and if they were seasonally affected (season consistent with exposure
to insects, ie, spring to fall exacerbation). Because clinical signs of IBH
are typical, 1 season of observed clinical signs was sufficient to qualify.
The HOARSI was used to grade EA severity and has been previously
described and validated.16–18 The HOARSI also referred to the most
severe clinical signs in the horse's history. Horses graded HOARSI 1 were
classified as healthy, whereas HOARSI 2 (mild), HOARSI 3 (moderate),
and HOARSI 4 (severe) were consistent with EA. Because increased
allergen-specific IgE concentrations have only been described in the
severe form of EA,13,14 horses for this group were selected based on the
following parameters: HOARSI ≥3 and partial pressure of arterial oxy-
gen <90 mm Hg, measured as described in the 3 previous studies.2,16,17
The control horses had no clinical signs or owner-reported history
of IBH or severe EA. To help avoid false-negative control animals, all
horses had to have spent at least 1 warm season (spring to fall) in
Switzerland exposed to Culicoides and also had to be exposed
previously to hay for at least 2 months.
2.3 | Allergens
The IgE concentrations specific to the 15 different r-allergens were
measured in the horse sera. Detailed information about the allergens
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used is given in Table 1. They consisted of 4 r-A. fumigatus allergens,
expressed and purified as previously described,19,20 8 r-Culicoides
allergens, 4 derived from Culicoides obsoletus, and 4 from
C. nubeculosus, all also expressed in Escherichia coli and purified as
described in a previous study.21 The Culicoides allergens were chosen
based on unpublished data showing that these r-Culicoides allergens
were the most relevant ones for horses in Switzerland. Additionally, in
an exploratory study, 1 commercially available r-allergen from the
mold C. herbarum (Cla h 8; Biomay AG, Vienna, Austria) and 2 r-mite
allergens, D. pteronyssinus 23 (Der p 23; Biomay AG) expressed in
Escherichia coli, and G. domesticus 2 expressed in Pichia pastoris (Gly d
2; Indoor Biotechnologies Inc, Charlottesville) were used.
2.4 | Allergen-specific IgE ELISA
Allergen-specific serum IgE against the different r-allergens was deter-
mined by ELISA, as described previously.22 Briefly, 96-well high-
binding polystyrene plates (Milian SA, Geneva, Switzerland) were
coated with 2 μg/mL of the allergen in coating buffer (0.2 M
carbonate-bicarbonate buffer pH 9.4) at 37C for 2 hours. After
washing the plates twice in washing buffer (phosphate-buffered saline
[PBS] pH 7.4 containing 0.05% Tween 20), plates were blocked with
blocking buffer (PBS pH 7.4, 5% milk powder, 0.05% Tween 20) for
1 hour at 37C. All dilutions of serum samples and antibodies were
made with blocking buffer. After washing, test serum samples were
randomly added in duplicates to the plates at a dilution of 1 : 5 and
incubated at 4C overnight. After washing, a monoclonal mouse
antibody–specific for equine IgE (1 μg/mL, clone 3H10)23 was added
and incubated for 2 hours at room temperature (RT) on a shaker. After
washing, alkaline phosphatase–conjugated, affinity-purified goat-anti-
mouse IgG (1 : 2000; Jackson Immuno Research, Newmarket, UK) was
added and the plates developed using 1.5 mg/mL phosphatase
substrate (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) in 10%
diethanolamine (Carl Roth GmbH + Co. KG, Karlsruhe, Germany),
pH 9.8. After 2 hours, absorbance was measured as optical density at
405 nm (OD405 nm). ELISA results were shown as OD405 nm values
after a blank correction on the optical density and correction between
plates, as described in our study.8
Because of the individual reaction patterns of the horses to the
single r-allergens, the sum of IgE concentrations against all 8 tested
r-Culicoides allergens were calculated for each horse and used for
additional analyses. Accordingly, IgE concentrations to the mold or
the mite allergens were also summed up for analysis.
2.5 | Determination of total serum IgE
concentrations
Total IgE concentrations were determined in the sera of the horses as
previously described.23,24 Briefly, plates were coated with 1 μg/mL
monoclonal mouse anti-IgE 1C12 in coating buffer (0.05 M carbonate
buffer, pH 9.4) and incubated overnight at 4C. The plates were
washed with wash buffer (PBS 0.05% Tween, pH 7.4) and then
blocked with 100 μL blocking buffer (PBS Tween 0.5% BSA) for
30 minutes at RT. Dilutions of standard sera or horse sera (dilution
1 : 50) were made in blocking buffer, diluted serially 2-fold and incu-
bated at RT for 2 hours and 30 minutes. After washing, a biotin conju-
gate monoclonal mouse anti-equine IgE mAb 3H1023 was added and
incubated for a further 2 hours and 30 minutes. After a further wash,
100 μL of a 1 : 10 000 dilution Extravidin alkaline phosphatase
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) was added and
plates incubated for 1 hour, on a shaker, at RT. After a final wash, the
ELISA was developed with 1 mg/mL phosphatase substrate dissolved
in 10% diethanolamine pH 9.8 (Carl Roth GmbH Co. KG, Karlsruhe,
Germany). Plates were finally incubated in the dark, at RT, and were
TABLE 1 Recombinant (r) allergens used in the study
Allergens Name recombinant Function Genbank accession Number References
Molds
Aspergillus fumigatus r Asp f 4 Unknown AJ001732 Crameri et al (1999)20
r Asp f 6 MnSOD U53561 Crameri et al (1999)20
r Asp f 7 Unknown AJ223315 Crameri et al (1999)20
r Asp f 8 Ribosomal P2 protein AJ224333 Mayer et al (1999)19
Cladosporium herbarum r Cla h 8 Mannitol dehydrogenase Commercial Biomay
Mites
Glycophagus domesticus r Gly d 2 NPC2 family Commercial Indoor biotechnologies
Dermatophagoides pteronyssinus r Der p 23 Peritrophin-like proteins Commercial Biomay
Culicoides
Culicoides obsoletus r Cul o 1P Kunitz BPI JX512273 Peeters et al (2013)8
r Cul o 2P D7-related JX512274 Peeters et al (2013)8
r Cul o 3 Antigen-5 like KC339673 Van der Meide et al (2013)7
r Cul o 6 D7-related KC339676 Van der Meide et al (2013)7
Culicoides nubeculosus r Cul n 3 Unknonwn HM145951 Schaffartzik et al (2011)21
r Cul n 4 Unknown HM145952 Schaffartzik et al (2011)21
r Cul n 5 Unknown HM145953 Schaffartzik et al (2011)21
r Cul n 9 D7-related HM145957 Schaffartzik et al (2011)21
Abbreviations: r Asp f, recombinant Aspergillus fumigatus; r Cla h, recombinant Cladosporium herbarum; r Cul n, recombinant Culicoides nubeculosus; r Der p,
recombinant Dermatophagoides pteronyssinus; r Gly d, recombinant Glycophagus domesticus.
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read after 30 minutes, 1 hour, and until the OD405 nm of the highest
concentration of the standard curve reached 1.00. As a standard, a
6-fold dilution of a horse serum with a known IgE concentration
ranging from 4 to 128 ng/mL was used. This sample was tested in
duplicate. The OD of the sera was introduced from the standard
curves to get their corresponding IgE concentration expressed as
ng/mL value and was subsequently multiplied by the dilution factor.
The concentration of the sera is shown as the mean of the values from
those dilutions where the concentration was within the standard
curve. All samples were randomly distributed on 8 plates.
2.6 | Statistical analyses
Statistical analyses were carried out using the statistical package
NCSS 2011 (NCSS Statistical Software, Kaysville, Utah). A 1st analysis
indicated that allergen-specific IgE concentrations were not
distributed normally; therefore, medians and ranges were used for
descriptive statistics.
The nonparametric Kruskal-Wallis Multiple-Comparison Z-Value
test (Dunn's test) with Bonferroni correction for multiple comparisons
was used to analyze differences in allergen-specific IgE concentrations
among the 4 groups of horses and for total serum IgE concentrations
in IBH, IBH/EA, and C horses from the most recent study.2 Before
merging the control horses from the 3 studies to a single control
group, IgE concentrations were tested for differences among controls
drawn from the 3 studies. The results are communicated accordingly.
Associations between EA or IBH and allergen-specific IgE concen-
trations were also tested in the Kruskal-Wallis Multiple-Comparison
Z-Value test by comparing horses with IBH to horses without IBH,
independently of a concomitant affection with EA. The same was
done for EA. Similarly, EA-affected horses were also compared to
horses without EA (Table 3).
To analyze a possible effect of the IBH severity score on specific
IgE, horses from Lanz et al (2017)2 were used. Because the number of
IBH-affected horses in each score group was too small for statistical
analysis, the horses with scores from 1 to 3, moderate IBH (see Sup-
porting Information Table S1), were pooled. Accordingly, horses with
more severe IBH (scores 4 and 5, severe IBH) were also pooled for
the analysis. Consequently, r-Culicoides allergen-specific IgE concen-
trations in the sera of horses without IBH (score = 0, n = 22), with
moderate IBH (score 1-3, n = 23), or severe IBH (score 4-5, n = 24)
were compared using a Kruskal-Wallis Multiple-Comparison Z-Value
test (Dunn's test) with Bonferroni correction for multiple comparisons.
The level of significance was set at P ≤ .05. Results are presented
as median (range).
3 | RESULTS
The total sample set included 105 horses of various breeds and sexes
(4 stallions, 54 mares, and 47 geldings) aged 3-27 years (Supporting
Information Table S1, Figure 1). There were no significant differences
in breed, age, or sex distribution among the 4 groups of horses (IBH,
IBH/EA, EA, and control horses) used in our study. A 1st analysis
showed that IgE concentrations in the sera of the group C from the
study by Lanz et al (2017)2 did not differ significantly from those of
group C horses derived from the studies by Rettmer et al (2014)16 and
Laumen et al (2010),17 except for r-Asp f 8, where group C
horses from the older studies had higher rAsp f 8-specific IgE
(OD405 = 0.10 nm [0.03-0.33 nm] versus 0.06 nm [0-0.36 nm],
P = .04, Mann Whitney U test). Thus, for this allergen, the results from
the samples from Lanz et al (2017)2 were analyzed separately from
those of the 2 other studies.16,17
The detailed data of total and allergen-specific IgE concentration
are presented in Table 2. The following results are summarized by
allergen classes.
3.1 | Allergen-specific IgE against midges
Comparison of r-Culicoides allergen-specific IgE concentrations in the
4 groups of horses showed that groups IBH and IBH/EA had
FIGURE 1 Demographics of the horse populations used in the 3 studies
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significantly higher IgE concentrations than group C or group EA
against r-Cul o 1P, r-Cul o 2P, and the sum of Culicoides allergen-
specific IgE (Table 2, Figure 2). Furthermore, groups IBH and IBH/EA
had significantly higher r-Cul o 3–specific IgE than group C. For r-Cul
o 6–specific IgE concentrations, the medians were only significantly
different from group EA and not from group C. The differences
between the groups for the r-Cul n allergens were statistically
significant for r-Cul n 3 and r-Cul n 4 (P ≤ .05), where horses of group
IBH had significantly higher IgE than group C. Nevertheless, IgE con-
centrations against each of the tested r-Culicoides allergens, including
the Cul n r-allergens, were significantly higher in horses with IBH
compared to horses without IBH, independently of the presence or
absence of EA (Supporting Information Table S2).
3.2 | Allergen-specific IgE against mold and mite
allergens
No significant differences among the 4 groups of horses were
detected for IgE concentrations against the mold allergens r-Cla h 8,
r-Asp f 4, r-Asp f 6, and r-Asp f 8 or the mite allergens r-Der p 23 and
r-Gly d 2. Group IBH/EA had significantly lower r-Asp f 7–specific IgE
than groups EA and C. No significant differences among the 4 horse
groups were found for r-Asp f 8.
3.3 | Total serum IgE concentrations
There was a high variation of total IgE concentrations among the
horses, with values ranging from 0 to 147.74 μg/mL (Table 2, Sup-
porting Information Figure 4).
However, a clinical diagnosis of IBH or of severe EA was not
associated with the total IgE concentrations observed in our popula-
tion. Group IBH (14.2 μg/mL [0-56.62 μg/mL]) and group IBH/EA
(10.8 μg/mL [0-147.74 μg/mL]) did not have significantly different values
when compared to group C (6.9 μg/mL [0-63.13] μg/mL; P = .37).
3.4 | Influence of IBH severity on allergen-specific
serum IgE concentrations
Grouping of the horses according to their IBH severity score (Table 3)
showed that horses with severe IBH had significantly higher serum
IgE concentrations against r-Cul o 1p, r-Cul o 2p, r-Cul o 3, r-Cul
n 3, and r-Cul n 4, and sum r-Cul compared to horses without IBH,
whereas horses with moderate IBH only had significantly higher IgE
against r-Cul o 1p, r-Cul o 6, r-Cul n 9, and sum r-Cul compared to the
C group. Horses with severe IBH did not have significantly higher IgE
concentrations to any of the tested allergens than horses with
moderate IBH.
TABLE 2 Results of allergen-specific IgE concentrations in horses sera
Allergens EA (N = 18) IBH (N = 24) IBH/EA (N = 23) Control (N = 40)
P-value
1-way ANOVA
r Cul o 1P 0.089a,b (0.001-2.29) 0.65a,c (0.033-3.11) 0.76b,d (0.01-3.096) 0.073c,d (0.001-0.41) <.001
r Cul o 2P 0.033a,d (0-0.086) 0.23a,c (0.003-3.19) 0.13b,d (0.004-3.25) 0.047c,d (0-0.98) <.001
r Cul o 3 0.074 (0.01-0.19) 0.22a (0-3.22) 0.087b (0-3.42) 0.04a,b (0-0.81) ≤.001
r Cul o 6 0.025a,b (0-0.087) 0.11a (0-3.22) 0.091b (0-3.22) 0.046 (0-0.27) ≤.001
r Cul n 3 0.12 (0.027-0.19) 0.24a (0.022-3.022) 0.12 (0.015-1.69) 0.11a (0.012-0.75) .01
r Cul n 4 0.08 (0-0.18) 0.151 (0-1.12) 0.13 (0-3.17) 0.095 (0-0.55) .052
r Cul n 5 0.044 (0.027-0.35) 0.086 (0.003-2.67) 0.088 (0-1.13) 0.057 (0-0.37) .089
r Cul n 9 0.08 (0.016-0.206) 0.105 (0.006-1.96) 0.16 (0-3.35) 0.082 (0-0.69) NS
Sum Culicoides 0.6a,b (0.2-2.9) 3.54a,c (0.48-15.067) 4.548b,d (0.46-17.15) 0.44c,d (0.21-2.052) <.001
r Asp f 4 0.067 (0-0.28) 0.023 (0-0.19) 0.038 (0-0.29) 0.043 (0-0.33) NS
r Asp f 6 0.098 (0-0.51) 0.17 (0-0.74) 0.12 (0-0.47) 0.16 (0-0.55) NS
r Asp f 7 0.057a (0.033-0.18) 0.031 (0-0.2) 0.016a,b (0-0.36) 0.048b (0-0.23) ≤.01
r Asp f 8 Lanz et al2 NA 0.045 (0-1.3) 0.069 (0-1.4) 0.057 (0-0.36) NS
r Asp f 8 Rettmer et al,16
Laumen et al17
0.123 (0.04-0.36) NA NA 0.102 (0.033-0.33) NS
r Cla h 8 0 (0-0.054) 0 (0-0.18) 0 (0-0.17) 0 (0-0.18) NS
Sum molds 0.35 (0.062-1.29) 0.333 (0.052-1.84) 0.36 (0.109-1.93) 0.338 (0.022-1.00) NS
r Der p 23 0.086 (0-0.31) 0.046 (0-0.72) 0.035 (0-0.74) 0.067 (0-0.27) NS
r Gly d 2 0.066 (0-0.34) 0.15 (0-0.31) 0.098 (0-0.69) 0.088 (0-0.33) NS
Sum mites 0.16 (0-0.66) 0.21 (0.038-0.93) 0.13 (0.004-0.9) 0.16 (0-0.5) NS
Total IgE* NA 14.19 (0-56.62) 10.81 (0-63.13) 6.88 (0-63.13) NS
Sum all IgE 1.011a,b (0.33-4.36) 3.97a,c (0.96-16.77) 3.78b,d (0.84-20.67) 1.24c,d (0.43-2.86) <.001
Abbreviations: EA, equine asthma; IBH, insect bite hypersensitivity; IgE, immunoglobulin E; NS, nonsignificant; NA, not analyzed; r Asp f, recombinant
Aspergillus fumigatus; r Cla h, recombinant Cladosporium herbarum; r Cul n, recombinant Culicoides nubeculosus; r Der p, recombinant Dermatophagoides pter-
onyssinus; r Gly d, recombinant Glycophagus domesticus.
Median OD405 (range) of IgE concentrations in sera of horses affected with severe EA, IBH, both IBH and EA, and in non-affected control horses. Same
superscript letters indicate statistically significant differences (P ≤ .05) in Kruskal-Wallis Z-value test.
*Only tested in sera from study by Lanz et al (2017),2 that is, control horses n = 22.
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FIGURE 2 Serum immunoglobulin E (IgE) concentrations (presented as optical density [at 405 nm {OD405 nm}] values) specific for recombinant
Culicoides obsoletus (Cul o; A-D) or Culicoides nubeculosus (Cul n; E) allergens and the sum of Cul o–specific and Cul n–specific IgE (sum Cul; F) in
the sera of horses affected with severe equine asthma (group EA), insect bite hypersensitivity (group IBH), or both EA and IBH (group IBH/EA)
and in healthy control horses (group C). Each dot represents the value of a single horse, and the red lines representing the median. * indicates
significant differences among the groups in the Kruskal-Wallis Multiple-Comparison Z-Value test (Dunn's test) with Bonferroni correction
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4 | DISCUSSION
The major findings of our study are that horses affected both with
IBH and EA do not have higher IgE concentrations to any of the
tested r-allergens, compared to horses affected with IBH only or with
EA only, whereas horses with IBH had significantly higher IgE concen-
trations against r-Culicoides allergens than horses without this condi-
tion, independently of a concomitant affection with EA. Contrarily,
the presence or absence of EA did not influence these IgE concentra-
tions (Table 2, Supporting Information Table S2). Our findings confirm
previous studies,22,25,26 which demonstrate that IBH-affected horses
have increased IgE concentrations against r-Culicoides allergens. How-
ever, the impact of additional hypersensitivity disease on serum IgE
concentrations in horses has so far not been investigated. In line with
previous studies, IBH-affected horses display individual IgE-binding
patterns to r-Culicoides allergens.21 For some allergens, only a few
horses with IBH had increased serum IgE concentrations (eg, to r-Cul
o 6 and r-Cul n 3), whereas for other allergens such as r-Cul o 1p, a
majority had increased specific IgE concentrations. Horses in group
EA, with the exception of 1 individual (Figure 2), were not sensitized
to r Culicoides allergens. Conversely to earlier studies,13,14,27 we did
not find increased IgE concentrations specific for the 2 r Asp f aller-
gens, r-Asp f 7 and r-Asp f 8, in the EA-affected group. Surprisingly,
group IBH/EA had significantly lower r-Asp f 7–specific IgE than
groups EA and C. We cannot explain these results, but the IgE con-
centrations against r-Aspf 7 were extremely low in all groups;
therefore, this finding is probably not biologically relevant (Supporting
Information Figure S1A). The difference of our findings to these previ-
ous studies might be because of the different horse populations and
possibly also environmental factors, that is, exposure to moldy hay.
Furthermore, in a previous study,13 the horses were all living in the
same stable, that is, environmental effects were more homogenous
than in the present study. Although IgE concentrations to r-Asp f
7 were very low in all tested samples, a few horses in groups IBH
(n = 2) and IBH/EA (n = 3) had high r-Asp f 8–specific IgE in their sera
(OD405 > 0.5; Supporting Information Figure S1B). This could be
explained by the development of IgE autoimmunity, as described in
severe allergic diseases in human patients. The presence of autoim-
mune reactions against phylogenetically highly conserved intracellular
proteins such as the ribosomal P2 protein have been described in
severe atopic diseases and is the result of cross-reactivity.19 r-Asp f
8 is a ribosomal P2 protein from A. fumigatus. Human patients with
severe allergic bronchopulmonary aspergillosis have high serum IgE
concentrations and positive skin tests both to A. fumigatus ribosomal
protein P2 and to its human counterpart.19 As these cytoplasmic pro-
teins are unlikely to be accessible for antigen-antibody interactions
under normal circumstances, this leads to the hypothesis that IgE
autoreactivity could be a consequence of tissue damage and release
of autoantigens at the site of inflammation. Indeed, skin integrity is
often markedly compromised in IBH, which would favor this
pathophysiological mechanism.19
TABLE 3 Results of allergen-specific IgE concentrations in horses sera
Allergens Healthy horses (N = 22) Moderate IBH (1-3) (N = 23) Severe IBH (4-5) (N = 24)
P-value
1-way ANOVA
r Cul o 1P 0.081a,b (0.001-0.33) 0.76b (0.033-3.11) 0.65a (0.01-3.061) <.001
r Cul o 2P 0.051a (0-0.98) 0.084 (0.004-3.13) 0.37a (0.003-3.25) ≤.01
r Cul o 3 0.033a (0-0.81) 0.087 (0-3.43) 0.28a (0-3.223) ≤.001
r Cul o 6 0.055a (0-0.265) 0.096a (0-3.23) 0.11 (0-0.82) .032
r Cul n 3 0.097a (0.019-0.75) 0.12 (0.022-3.022) 0.24a (0.015-2.78) .032
r Cul n 4 0.084a (0-0.55) 0.082 (0-1.83) 0.15a (0.027-3.17) .017
r Cul n 5 0.068 (0-0.37) 0.104 (0-2.67) 0.078 (0-0.68) NS
r Cul n 9 0.069a (0-0.69) 0.17a (0-3.35) 0.081 (0.006-1.051) .024
Sum Culicoides 0.65a,b (0.33-2.11) 3.18b (0.49-19.41) 3.75a (0.54-12.66) .001
r Asp f 4 0.048 (0-0.33) 0.049 (0-0.29) 0.025 (0-0.13) NS
r Asp f 6 0.16 (0-0.55) 0.17 (0-0.74) 0.12 (0-0.558) NS
r Asp f 7 0.036 (0-0.23) 0.023 (0-0.36) 0.029 (0-0.2) NS
r Asp f 8 0.057 (0-0.36) 0.067 (0-1.41) 0.049 (0-1.3) NS
r Cla h 8 0 (0-0.18) 0 (0-0.18) 0 (0-0.044) NS
Sum molds 0.28 (0.022-0.99) 0.36 (0.11-1.93) 0.31 (0.051-1.84) NS
r Der p 23 0.058 (0-0.21) 0.035 (0-0.742) 0.061 (0-0.72) NS
r Gly d 2 0.095 (0-0.33) 0.095 (0.004-0.69) 0.15 (0.007-0.32) NS
Sum mites 0.15 (0-0.5) 0.13 (0.004-0.904) 0.24 (0.038-0.93) NS
Total IgE 6.88 (0-63.13) 10.92 (0-147.74) 12.07 (0-56.62) NS
Sum IgE-specific 1.35a,b (0.43-2.86) 3.68b (0.97-20.67) 4.14a (0.84-13.97) <.001
Abbreviations: IBH, insect bite hypersensitivity; IgE, immunoglobulin E; NS: nonsignificant; r Asp f, recombinant Aspergillus fumigatus; r Cla h, recombinant
Cladosporium herbarum; r Cul n, recombinant Culicoides nubeculosus; r Cul o, recombinant Culicoides obsoletus; r Der p, recombinant Dermatophagoides ptero-
nyssinus; r Gly d, recombinant Glycophagus domesticus.
Horses were grouped depending on the IBH severity grade. Median OD405 (range) of IgE levels in sera of horses affected with moderate (IBH score 1-3) or
severe (IBH score 4-5) IBH and in healthy control horses. The analysis was performed with sera of the horses from the study by Lanz et al (2017).2 Same
superscript letters indicate statistically significant differences (P ≤ .05) in Kruskal-Wallis Z-value test.
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Testing of novel, commercially available r-allergens from molds and
mites not previously investigated in the horse did not indicate that they
are relevant for EA or IBH. The limited number of potential allergens for
EA tested is certainly a limitation of this exploratory part of our study.
More efficient methods such as allergen chip arrays, which allow for
testing hundreds of allergens simultaneously, should be used in the
future for such purposes.28 To further test whether equine multiple
hypersensitivity disorder was not associated with a higher IgE response,
total serum IgE concentrations were then determined in the sera of
EA/IBH-affected horses in comparison to IBH-affected horses and the
corresponding healthy controls. Again, no significant differences
between the EA/IBH and IBH groups were found. Total IgE concentra-
tions were not determined in the sera from the horses derived from the
2 oldest studies16,17 because of these negative results and because pre-
vious studies had demonstrated that RAO-affected horses do not have
significantly different total IgE concentrations than control horses.24
The high variation of IgE concentrations in the sera of the tested horses,
independent of the clinical diagnosis, suggests that these horses were
probably infected to varying degrees with endoparasites. Parasite infec-
tion increases total serum IgE concentrations in the horse as in other
species.29 Unfortunately, no data on endoparasite infestation were
available for the horses included in our study. And thus the data on total
IgE should be interpreted with caution.
IBH severity can affect Culicoides-specific IgE reactivity.8 In the
present study, horses suffering from severe IBH have, compared to
healthy controls, significantly increased IgE concentrations to more
r-Culicoides allergens (5 allergens) compared to horses with moderate
IBH that only had significantly higher IgE to 3 r-Culicoides allergens.
Nevertheless, no significant differences in allergen-specific IgE con-
centrations between horses with severe and moderate IBH were
found (Table 3). This could be because the IBH score was based on
the most severe clinical signs the horse had experienced in life and
not on the IBH severity at the time of blood sampling. Furthermore,
contrarily to the C group, where the variance of Culicoides r-allergens
was low, the variance was much higher in the moderate and severe
IBH groups (ie, in both IBH groups, horses with high IgE levels to Culi-
coides r-allergens were found). Given this large variation in the
affected horses and the moderate numbers in these groups, insuffi-
cient power may have led to type II errors, that is, failure to detect dif-
ferences between groups of moderate and severe IBH. Most IBH
horses were protected from insect bites by blankets or use of repel-
lents. This reduced exposure to the causative allergens likely resulted
in a decrease of specific IgE concentrations. Interestingly, only the
horses with moderate but not with severe IBH had significantly higher
IgE to r-Cul o 6 and r-Cul n 9 compared to controls. This might indi-
cate differences in the allergic skin response depending on the aller-
gen to which an individual is sensitized. However, this finding would
need to be confirmed in a larger set of horses. The allergens r-Cul o
6 and r-Cul n 9 both belong to the D7 protein family, expressed in sal-
ivary glands of Diptera. They have been shown to bind serotonin, his-
tamine, and norepinephrine and thus antagonize platelet aggregation,
vascular contraction, and pain.30 The fact that sera were drawn from
3 different studies, which was because of the availability of the
IBH/EA group (a valuable collection of rare multiple hypersensitivity
phenotypes), which had to be complemented by a severe EA group,
entails several limitations and potential pitfalls. This includes potential
confounders regarding case and group definitions, as well as bias
through differences in allergen exposure between the groups that
were compared. The potential confounder by differences in exposure
is already discussed above, specifically regarding comparisons with
studies using more homogenous exposure conditions.13 However, the
3 studies2,16,17 from which samples were used were all performed in
the same restricted geographical area of central and Western Switzer-
land within a 10-year period. Thus, relevant differences in allergen
exposure between the populations used in our study are unlikely. Fur-
thermore, although the serum samples originated from horses from
3 different studies, the same questionnaire was consistently used in
all horses, specifically the well-validated HOARSI classification as well
as thorough clinical and complementary examinations. Importantly,
assessment for occurrence of other hypersensitivity diseases such as
IBH or recurrent urticaria was performed in all 3 studies (Supporting
Information Table S1).16–18
In conclusion, our study shows that r-Culicoides-specific serum
IgE in IBH is not associated with concurrent severe EA. Thus, the
clinically documented increased risk of IBH horses to develop
severe EA does not seem to be influenced by a concomitant
increase in total or allergen-specific IgE concentrations. Further
studies using a larger panel of r-allergens, for example, by using
an allergen chip array and larger numbers of horses to reduce
type 2 errors are warranted.
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